Stock Ratings / Health Care / UPC / insiders

CURX (37) KPRX (32) TCRT (31) MTVA (47) ⌘ Pro Terminal →

Universe Pharmaceuticals Inc. (Class A) (UPC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are UPC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies UPC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.54 -20.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.48

Universe Pharmaceuticals Inc. (Class A) (UPC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $7.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.48 (-3.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UPC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY UPC SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 35.3% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.15-5.3% Next Q

Q2 (-2Q)

Grade E$3.93+10.4% Next Q

Q3 (-1Q)

Grade E$4.34-64.5% Next Q

Current

Grade E$1.54-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a UPC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While UPC currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.22) and Max Pain ($1.62) forces dealer call-delta covering toward $18.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UPC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UPC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

UPC Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (UPC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on UPC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UPC)

✓Walkthrough of UPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.32%▼ SUPPORT BREAKDOWN

2026-10-30O $1.50H $1.67L $1.45C $1.54VOL 548.8K

RES: $4.26SUP: $3.90SMA50: $4.22SMA200: $3.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UPC Butterfly Map → + Track UPC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -22.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on UPC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UPC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UPC)

Health Care Rank #884 of 1016 ⚔️ CURX vs UPC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UPC vs. CURX, KPRX, TCRT, MTVA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Universe Pharmaceuticals Inc. (Class A) (UPC) ranks #884 by composite RQD confidence (33/100, grade E) and #917 by equity capitalization ($7.7M). Within this direct 5-issuer industry benchmark cohort, UPC leads on earnings valuation at N/A trailing P/E, while CURX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MTVA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with UPC at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UPC ACTIVE Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-20.21%	$7.7M	Benchmark Subject
CURX Curanex Pharmaceuticals Inc	D-	37/100	—	—	-35.0%	-0.20%	$7.7M	/curx-vs-upc →
KPRX Kiora Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	-25.42%	$7.8M	/kprx-vs-upc →
TCRT Alaunos Therapeutics Inc.	E	31/100	—	—	-35.0%	-11.27%	$7.8M	/tcrt-vs-upc →
MTVA MetaVia Inc.	D	47/100	—	—	-35.0%	+4.39%	$7.8M	/mtva-vs-upc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001809616

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Universe Pharmaceuticals Inc. (Class A) (UPC) reported GAAP revenue of $17.86B (-22.4% vs. FY2024 revenue of $23.02B , and -44.7% cumulative change since FY2023) , GAAP net income of -$3.67B, operating cash flow of -$5.05B, and free cash flow of -$5.32B (+45.2% YoY). On the balance sheet, UPC closed FY2025 with $69.30B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$17.86B	-$3.67B	-$5.05B	-$5.32B	$69.30B	—
FY2024 (FY)	2024-09-30	$23.02B	-$8.73B	-$9.51B	-$9.72B	—	—
FY2023 (FY)	2023-09-30	$32.31B	-$6.58B	$1.12B	$1.12B	—	—

3. UPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Universe Pharmaceuticals Inc. (Class A) (NASDAQ: UPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.54 (-20.21% 1D, market cap $7.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, UPC ranks #884 in composite RQD confidence.

How does UPC compare to CURX and KPRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UPC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 35.3%, and ROIC of —. By comparison, CURX (Curanex Pharmaceuticals Inc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M) and KPRX (Kiora Pharmaceuticals Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, UPC leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for UPC?

Per UPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001809616), Universe Pharmaceuticals Inc. (Class A) generated $17.86B in revenue (-22.4% YoY), -$3.67B in net income, and -$5.32B in free cash flow against $69.30B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is UPC trading relative to its 50-day, 200-day, and 52-week technical levels?

UPC last traded at $1.54 (-20.21% on volume of 980,963 shares), positioning the stock -63.51% below its 50-day simple moving average ($4.22) and -59.69% below its 200-day simple moving average ($3.82). Across its 52-week range of $1.45 to $17.96, UPC sits at the 0.5% percentile with a 14-day RSI of 22.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.35 to $1.73).

UPC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are UPC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies UPC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: UPC RQD Cockpit UPC 12M Forecast UPC Earnings & Move UPC Dividends & DRIP UPC Insiders & 13F UPC Whale Options UPC Profit Sankey UPC News & Why